Tactile Systems

Tactile Systems Technology, Inc. is a medical technology company. It develops and provides innovative medical devices for the treatment of chronic diseases at home. The firm focus on advancing the standard of care in treating chronic diseases in the home setting to improve patient outcomes and quality of life and help control rising healthcare expenditures. The company was founded on January 30, 1995 and is headquartered in Minneapolis, MN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Tactile Systems reports strong Q4 earnings, eyes growth and innovation

Tactile Systems delivered impressive Q4 2022 results with strong revenue growth, positive net income, and operational advancements, positioning the company for future success.
Strategic priorities for 2023 focus on sales team productivity, new product innovation, and operational efficiency, highlighting a commitment to sustained growth and market leadership.
Challenges include managing sales force turnover, supply chain constraints, and financial complexities post-2023, requiring proactive solutions and strategic decision-making.
Opportunities lie in capitalizing on revenue growth momentum, new product developments, and achieving an expanded adjusted EBITDA profile, signaling potential for continued success and value creation.

Tactile Systems reports robust Q1 growth, focuses on innovation

Tactile Systems delivered strong financial performance and operational advancements in Q1 2023, showcasing growth potential and a commitment to innovation and patient care.
While facing challenges in supply chain readiness and operational efficiency, the company's strategic focus on enhancing Medicare processes and product development presents opportunities for future success.
Overall, Tactile Systems' earnings call highlighted a positive trajectory with increased revenue guidance, product innovation, and a dedication to improving patient outcomes and support.

Tactile Systems (TCMD) reports strong Q2 earnings and growth outlook

Tactile Systems (TCMD) showcased robust financial performance, operational efficiency gains, and strategic talent additions in Q2 2023.
While facing challenges like AffloVest sales slowdown, the company raised revenue guidance and expects strong profitability with adjusted EBITDA of $25-27 million for 2023.
Opportunities lie in the head and neck trial's potential impact on revenue, Kylee app engagement benefits, and strategic priorities driving growth.

Tactile Systems reports revenue growth and strategic initiatives progress

Tactile Systems' Q3 performance showed revenue growth and improved profitability, supported by strategic initiatives and margin improvement efforts.
While facing challenges in AffloVest sales and patient acquisition, the company is optimistic about opportunities in therapy expansion and operational enhancements.
Consistent price increases and focus on technology-driven efficiencies are key strengths, with a focus on achieving ambitious 2025 targets.
Overall, Tactile Systems is navigating challenges while capitalizing on opportunities for growth and operational optimization.

Tactile Systems posts robust Q4 results, eyes growth opportunities

Tactile Systems delivered strong financial performance in Q4 2023, with revenue and net income growth. The company provided optimistic revenue guidance for 2024 and outlined strategic priorities for driving growth and enhancing customer experience. Challenges include anticipated headwinds and limited margin gains in the short term.

Tactile Systems reports Q1 growth, doubles EBITDA, eyes tech expansion

Tactile Systems reported solid financial performance with revenue growth and doubled adjusted EBITDA.
The company is strategically investing in tech advancements, new products, and expanding sales channels.
Challenges include addressing declining airway clearance revenues and optimizing sales rep impact.
Opportunities lie in expanding clinical trials, enhancing product user experience, and leveraging tech investments.

Tactile Systems (TCMD) reports robust Q2 earnings amidst Medicare challenges

Tactile Systems' Q2 2024 performance reflects solid financial growth and strategic initiatives. While facing challenges from Medicare documentation requirements, the company is focused on adapting to regulatory changes. Opportunities lie in capital allocation strategies, technology advancements, and market expansion efforts.

Tactile Systems reports Q3 growth, faces documentation challenges and opportunities

Tactile Systems delivered solid Q3 performance with revenue growth and improved EBITDA, despite challenges in sales productivity.
The company's strategic strengths lie in strong market demand, product innovation, and a shareholder-friendly capital allocation strategy.
Navigating challenges related to regulatory changes and operational efficiency while capitalizing on growth opportunities will be key for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tactile Systems Technology, Inc. engages in developing and providing medical devices for the treatment of underserved chronic diseases. It provides lymphedema solutions and offers Flexitouch Plus and Entre Plus systems products. The company was founded on January 30, 1995 and is headquartered in Minneapolis, MN.

Appoints Valerie Asbury and Brent Shafer Appoints Valerie Asbury and Brent Shafer

Tactile Medical Announces New Appointments to Board of Directors

Griffon

National Health Investors

Ranger Oil Corp

US Foods Holding

GFF, NHI, ROCC, USFD, and TCMD have been added to the Zacks Rank #5 (Strong Sell) List on December 31, 2021.

New Strong Sell Stocks for December 31st

Custom Truck One Source

Gannett Co.

Illumina

Detecting toxic stocks and dumping them at the right time is crucial to avoid big losses. ILMN, TCMD, CTOS and GCI are a few toxic stocks that don't deserve a place in your portfolio.

4 Toxic Stocks to Eliminate From Your Portfolio Now

Stoneridge

Precisely figuring out toxic stocks and discarding or short selling those at the right time is the key to safeguarding your portfolio from big losses.

Don't Squander Your Income on These 3 Toxic Stocks

Tactile Systems Technology, Inc. (TCMD) CEO Dan Reuvers on Q3 2021 Results - Earnings Call Transcript

Tactile Systems Technology (TCMD) delivered earnings and revenue surprises of -161.54% and -7.94%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Tactile Systems Technology (TCMD) Reports Q3 Loss, Lags Revenue Estimates

Third Quarter Revenue Increased 7% Year-Over-Year; First Nine Months Revenue Increased 14% Year-over-Year Third Quarter Revenue Increased 7% Year-Over-Year; First Nine Months Revenue Increased 14% Year-over-Year

Tactile Systems Technology, Inc. Reports Third Quarter 2021 Financial Results; Updates Full Year 2021 Outlook

Tactile Systems Technology (TCMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tactile Systems Technology (TCMD) Earnings Expected to Grow: Should You Buy?

Tactile Systems Technology (TCMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Tactile Systems Technology (TCMD) Moves 6.2% Higher: Will This Strength Last?

MINNEAPOLIS, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq:TCMD), a medical technology company focused on developing medical devices for the treatment of underserved chronic diseases at home, today announced that third quarter of fiscal year 2021 financial results will be released after the market closes on Monday, November 8th.

Tactile Medical to Release Third Quarter of Fiscal Year 2021 Financial Results on November 8, 2021

MINNEAPOLIS, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq: TCMD), a medical technology company focused on developing medical devices for the treatment of chronic diseases at home, today announced the enrollment of the first patient in a randomized, controlled clinical trial evaluating the effectiveness of its Flexitouch ® Plus system for the treatment of head and neck lymphedema.

Tactile Medical Announces Enrollment of First Patient in Randomized, Controlled Clinical Trial Evaluating the Effectiveness of Flexitouch® Plus for the Treatment of Head and Neck Lymphedema

MINNEAPOLIS, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical” or the “Company”) (Nasdaq: TCMD), a medical technology company focused on developing medical devices for the treatment of underserved chronic diseases at home, today announced it has acquired the assets of the AffloVest respiratory therapy business from International Biophysics Corporation, a privately-held company which developed and manufactures AffloVest.

Tactile Medical Announces Acquisition of AffloVest®

MINNEAPOLIS, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq: TCMD), a medical technology company focused on developing medical devices for the treatment of chronic diseases at home, today announced that management will participate in the Morgan Stanley 19th Annual Global Healthcare Conference, which is being held virtually from September 9th-10th and 13th-15th. Management will participate in a fireside chat on Thursday, September 9th at 4:15 p.m. Eastern Time.

Tactile Medical to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

MINNEAPOLIS, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq: TCMD), a medical technology company focused on developing medical devices for the treatment of chronic diseases at home, today announced that management will participate in the Guggenheim 2021 MedTech Disruptors Summit, which is being held virtually from August 9th-10th. Management will participate in a fireside chat on Monday, August 9th at 3:00 p.m. Eastern Time.

Tactile Medical to Present at the Guggenheim 2021 MedTech Disruptors Summit

Tactile Systems Technology, Inc. (TCMD) CEO Dan Reuvers on Q2 2021 Results - Earnings Call Transcript

Tactile Systems Technology (TCMD) delivered earnings and revenue surprises of 100.00% and 2.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Tactile Systems Technology (TCMD) Reports Break-Even Earnings for Q2

Shares of Tactile Systems Tech (NASDAQ:TCMD) were flat in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 113.73% year over year to $0.07, which beat the estimate of $0.01.

Recap: Tactile Systems Tech Q2 Earnings

Second Quarter Revenue Increased 45% Year-Over-Year; First Half Revenue Increased 19% Year-over-Year Second Quarter Revenue Increased 45% Year-Over-Year; First Half Revenue Increased 19% Year-over-Year

Tactile Systems Technology, Inc. Reports Second Quarter 2021 Financial Results; Updates Full Year 2021 Outlook

Will Tactile Systems Technology (TCMD) Report Negative Earnings Next Week? What You Should Know

MINNEAPOLIS, June 29, 2021 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq:TCMD), a medical technology company focused on developing medical devices for the at-home treatment of chronic diseases, today announced that second quarter of fiscal year 2021 financial results will be released after the market closes on Monday, August 2nd.

Tactile Medical to Release Second Quarter of Fiscal Year 2021 Financial Results on August 2, 2021

MINNEAPOLIS--(BUSINESS WIRE)--Pelvital announces that Jerry Mattys has joined its Board of Directors.

Gerald R. (Jerry) Mattys Joins Pelvital USA, Inc. Board of Directors

MINNEAPOLIS, May 18, 2021 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq: TCMD), a medical technology company focused on developing medical devices for the treatment of chronic diseases at home, today announced that management will participate in the William Blair 41st Annual Growth Stock Conference, which is being held virtually from June 1st-3rd. Management will participate in a fireside chat on Tuesday, June 1st at 8:40 a.m. Central Time.

Tactile Medical to Present at the William Blair 41st Annual Growth Stock Conference

Tactile Systems Technology, Inc. (TCMD) CEO Daniel Reuvers on Q1 2021 Results - Earnings Call Transcript

Shares of Tactile Systems Tech (NASDAQ:TCMD) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were down 140.00% year over year to ($0.12), which beat the estimate of ($0.15).

Tactile Systems Tech: Q1 Earnings Insights

MINNEAPOLIS, May 03, 2021 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq: TCMD), a medical technology company focused on developing medical devices for the at-home treatment of chronic diseases, today reported financial results for the first quarter ended March 31, 2021.

News for Tactile Systems Stock (TCMD)